XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including ...
XORTX Therapeutics Inc. (NASDAQ: XRTX) is a drug-based biotechnology and biopharmaceutical company building therapies aimed at correcting and managing disease biology linked to abnormal purine metabolism and hyperuricemia (high serum uric acid). A core theme in the company’s strategy is improving outcomes for patients with progressive kidney disorders and related ...XORTX Therapeutics Inc. (NASDAQ: XRTX) is a drug-based biotechnology and biopharmaceutical company building therapies aimed at correcting and managing disease biology linked to abnormal purine metabolism and hyperuricemia (high serum uric acid). A core theme in the company’s strategy is improving outcomes for patients with progressive kidney disorders and related systemic complications.
Business and platform focus: XORTX develops and advances small-molecule clinical candidates that target uric-acid pathways—particularly through xanthine oxidase inhibition and related mechanisms. By addressing upstream drivers such as hyperuricemia and its downstream relationship to kidney injury and progression, the company positions its programs across multiple kidney-focused indications rather than a single rare disease.
Products and pipeline: The provided company description highlights several key late-stage and development programs. XRx-008 is described as a late-stage clinical program for autosomal dominant polycystic kidney disease (ADPKD). XRx-101 is an agent intended to reduce uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. XRx-221 is described as a series of xanthine oxidase inhibitors developed for management of diabetic nephropathy. Additional pipeline references in the provided snippets mention XRx-026 for gout and indicate multiple programs underway.
Services and collaborations: XORTX also collaborates with academic medical researchers, including the Icahn School of Medicine, to study acute kidney injury and hyperuricemia in hospitalized COVID-19 patients. Such collaborations typically support clinical research design, patient recruitment, and scientific validation of endpoints.
Scale and operating model: The company is relatively small in headcount (shown as 2 full-time employees in the provided dataset) and appears to be in the 11–50 employee range per LinkedIn-based information. This scale is consistent with many clinical-stage biopharmaceutical firms that rely on outsourced CRO/CMO services, clinical site networks, and partner-led studies.
Cost and BOM considerations: As a clinical-stage company, much of the company’s cost structure is typically dominated by R&D expenditures (clinical trials), regulatory and compliance costs, and external service spend (CROs, lab work, manufacturing and testing batches), rather than an internal “bill of materials” manufacturing model like traditional industrial firms.
Financial and investment perspective: The provided financial ratios indicate profitability pressure typical of pre-commercial or late-stage clinical companies, with negative return metrics (e.g., negative ROA/ROE) in the latest snapshot. The balance sheet shows liquidity measures such as a current ratio above 1 in the dataset, which can help fund ongoing clinical activities; however, value creation depends on clinical results, regulatory milestones, and successful commercialization prospects.
Key people: Dr. Allen W. Davidoff is identified as the founder and President/CEO, with prior drug development and regulatory experience.
Wishes/near-term priorities (implied by pipeline stage): Near-term success for XORTX is likely tied to advancing clinical programs (e.g., ADPKD and other kidney-related indications), generating strong efficacy/safety data, and progressing toward regulatory submissions where applicable. Continued funding and milestone achievement are typically central to sustaining development through late-stage clinical phases.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-2.7M
+15.8%
-109.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-2.8M
+24.2%
+100.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
1.8%
+53.9%
-100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.61x
-54.3%
+732.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
